lyophilised powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-04. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
== Awards == The Norm Smith Medal was awarded to Brian Lake of Hawthorn. The Brownlow Medal was awarded to Gary Ablett Jr. of Gold Coast, who received 28 votes. The AFL Rising Star was awarded to Jaeger O'Meara of Gold Coast, who received 44 votes. The Coleman Medal was awarded to Jarryd Roughead of Hawthorn, who kicked 68 goals during the home and away season. The McClelland Trophy was awarded to Hawthorn for the second year in a row. The Wooden Spoon was "awarded" to Greater Western Sydney for the second year in a row. The AFL Players Association awards The Leigh Matthews Trophy was awarded to Gary Ablett Jr. of Gold Coast for a record fifth time. The Robert Rose Award was awarded to Joel Selwood of Geelong for the second year in a row and third time overall. The Best Captain was awarded to Joel Selwood of Geelong. The Best First-Year Player was awarded to Jaeger O'Meara of Gold Coast. The AFL Coaches Association Awards were as follows: The Player of the Year Award was given to Scott Pendlebury of Collingwood, who received 96 votes. The Allan Jeans Senior Coach of the Year Award was awarded to Ken Hinkley of Port Adelaide The Assistant Coach of the Year Award was awarded to Robert Harvey of Collingwood. The Development Coach of the Year Award was awarded to Chris Maple of Western Bulldogs. The Support Staff Leadership Award was awarded to Stephen Wells of Geelong. The Lifetime Achievement Award was awarded to George Stone. The Best Young Player Award was awarded to Jeremy Cameron of Greater Western Sydney.
=== Basic tools === The chemoproteomic toolkit is anchored by liquid chromatography-tandem mass spectrometry (LC-MS/MS or LC-MS) based quantitative proteomics, which allows for the near complete identification and relative quantification of complex proteomes in biological samples. In addition to proteomic analysis, the detection of post-translational modifications, like phosphorylation, glycosylation, acetylation, and recently ubiquitination, which give insight into the functional state of a cell, is also possible. The vast majority of proteomic studies are analyzed using high-resolution orbitrap mass spectrometers and samples are processed using a generalizable workflow. A standard procedure begins with sample lysis, in which proteins are extracted into a denaturing buffer containing salts, an agent that reduces disulfide bonds, such as dithiothreitol, and an alkylating agent that caps thiol groups, such as iodoacetamide. Denatured proteins are proteolysed, often with trypsin, and then separated from other mixture components prior to analysis via LC-MS/MS. For more accurate quantification, different samples can be reacted with isobaric tandem mass tags (TMTs), a form of chemical barcode that allows for sample multiplexing, and then pooled.
== External links == Center for Oral History. "Miguel A. Ondetti". Science History Institute. Bohning, James J. (12 January 1995). Miguel Angel Ondetti, Transcript of an Interview Conducted by James J. Bohning at Princeton, New Jersey on 12 January 1995 (PDF). Philadelphia, PA: Chemical Heritage Foundation. Hall of Fame, Inventor Profile: Miguel Ondetti
An egg case or egg capsule, often colloquially called a mermaid's purse, is the casing that surrounds the eggs of oviparous chondrichthyans. Living chondricthyans that produce egg cases include some sharks, skates and chimaeras. Egg cases typically contain one embryo, except for big skate and mottled skate egg cases, which contain up to seven embryos. Oviparity is completely absent in the superorder Squalomorphi. Egg cases are also thought to have been produced by some extinct chondrichthyan groups, such as hybodonts and xenacanths.
==== Glycosaminoglycans ==== Topical glycosaminoglycans supplements can help to provide temporary restoration of enzyme balance to slow or prevent matrix breakdown and consequent onset of wrinkle formation. Glycosaminoglycans (GAGs) are produced by the body to maintain structural integrity in tissues and to maintain fluid balance. Hyaluronic acid is a type of GAG that promotes collagen synthesis, repair, and hydration. GAGs serve as a natural moisturizer and lubricant between epidermal cells to inhibit the production of matrix metalloproteinases (MMPs).
Sources: en.wikipedia.org
Naturally occurring platinum (78Pt) consists of five stable isotopes (192Pt, 194Pt, 195Pt, 196Pt, 198Pt) and one long-lived (half-life 4.83×1011 years) radioisotope (190Pt). There are also 34 known synthetic radioisotopes ranging from 165Pt to 204Pt, and longest-lived of those is 193Pt with a half-life of 50 years. All the others have half-lives under two weeks, most under a day. There are numerous metastable states, of which the most stable are 193mPt and 195mPt with half-lives 4.33 and 4.010 days, decaying to their ground states. Despite the obstacles to measurement with rare isotopes of rare elements, with a very slow decay, the 190Pt/186Os system has been used in isotope geology, though not directly for dating. All isotopes of platinum are either radioactive or observationally stable, meaning that they are predicted to be radioactive but no actual decay has been observed. Platinum-195 is the most abundant isotope, making platinum one of the only three elements to have its most abundant isotope with an odd neutron number (the other two being beryllium and nitrogen); however, it is so only by a small margin, unlike the other two, and is more in the nature of a coincidence.
=== Pharmacokinetics === The pharmacokinetics of rasburicase were evaluated in both pediatric and adult patients with leukemia, lymphoma or other hematological malignancies. Rasburicase exposure, as measured by AUC0-24 hr and Cmax, tended to increase with a dose range from 0.15 to 0.2 mg/kg. The mean terminal half-life was similar between pediatric and adult patients and ranged from 15.7 to 22.5 hours. The mean volume of distribution of rasburicase ranged from 110 to 127 mL/kg in pediatric patients and from 75.8 to 138 mL/kg in adult patients, respectively. Minimal accumulation of rasburicase ( < 1.3 fold) was observed between days 1 and 5 of dosing. In adults, age, gender, baseline liver enzymes and creatinine clearance did not impact the pharmacokinetics of rasburicase. A cross-study comparison revealed that after administration of rasburicase at 0.15 or 0.20 mg/kg, the geometric mean values of body-weight normalized clearance were approximately 40% lower in Japanese (n=20) than that in Caucasians (n=22).
=== Newborn Screening (NBS) === Newborn screening (NBS) for missense mutations is increasingly incorporating genomic technologies in addition to traditional biochemical methods to improve the detection of genetic disorders early in life. Traditional NBS primarily relies on biochemical assays, such as tandem mass spectrometry, to detect metabolic abnormalities indicative of conditions like phenylketonuria or congenital hypothyroidism. However, these methods may miss genetic causes or produce ambiguous results. To address these deficiencies, next-generation sequencing (NGS) is being added to NBS programs. For instance, targeted gene panels and whole-exome sequencing (WES) are used to identify disease causing missense mutations in genes associated with treatable conditions, such as severe combined immunodeficiency (SCID) and cystic fibrosis. Studies like the BabyDetect project have demonstrated the utility of genomic screening in identifying disorders missed by conventional methods, with actionable results for conditions affecting more than 400 genes. In addition, genomic approaches allow for the detection of rare or recessive conditions that may not manifest biochemically at birth, significantly expanding the scope of diseases screened. These advancements align with the established principles of NBS, which emphasize early detection and intervention to prevent morbidity and mortality.
In October 2013, Basilea received marketing authorisation in twelve European countries, including Germany, for the distribution of the broad-spectrum antibiotic Ceftobiprole for the treatment of bacterial lung infections; in the following two years, the drug was gradually approved in other European countries and non-EU countries. Ceftobiprole has been approved in 32 countries and has been marketed in 21 countries since the end of 2023. In 2020, Basilea sold the group headquarters in Basel to the pension fund of the Swiss bank UBS by way of a sale-leaseback and moved to its new headquarters in Allschwil in mid-2022. The gross proceeds from the sale amounted to around CHF 19 million before fees and transaction costs. In 2021, Basilea Pharmaceutica China Ltd. was sold to the US company PHT International. Basilea was previously active in oncological research, but withdrew from it at the beginning of 2022 and has since been focusing purely on anti-infectives. In 2023, Basilea acquired the rights to the antifungal drug Fosmanogepix from Pfizer. By the end of 2023, Isavuconazole was commercialised in more than 70 countries, including the United States, most EU countries, China and Japan. Isavuconazole's total global sales in the twelve-month period between October 2022 and September 2023 amounted to CHF 406 million. This corresponds to growth of 22 per cent compared to the previous year.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.